Atea Pharmaceuticals, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Atea adopted a revised Non-Employee Director Compensation Program effective June 18, 2026, setting annual board retainer at $45,000 plus committee fees ($5,000–$26,000 depending on role), and granting initial equity awards of 129,200 share options and annual awards of 37,700 options plus 26,700 RSUs. Separately, on June 1, 2026, the company engaged consultant Bruno Lucidi at $25,000 per quarter for commercialization and reimbursement advisory services outside the U.S., with standard IP assignment and confidentiality provisions.
Why this rating
Routine board compensation reset and standard consultant engagement. Combined annual commitment <$200K relative to $262.6M market cap. No material strategic or financial impact.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.